Investors might want to bet on Apellis Pharmaceuticals, Inc. (APLS) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Apellis Pharmaceuticals, Inc. (APLS) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Apellis Pharmaceuticals, Inc. is one of 1071 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank gauges the ...

The market expects Apellis Pharmaceuticals, Inc. (APLS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the ...

WALTHAM, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company approved the grant of equity awards to 4 new employees with a grant date of February 1, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5 ...

Apellis Pharmaceuticals (APLS) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has voted against the approval of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).The negative opinion of the CHMP was expected as the company previously announced a negative trend vote on the marketing authorization application (MAA) for pegcetacoplan following an oral explanation meeting in ...

WALTHAM, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on the marketing authorization application (MAA) of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As previously announced, this opinion was expected based on a negative trend vote following an ora ...

One stock that might be an intriguing choice for investors right now is Apellis Pharmaceuticals, Inc. (APLS) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably ...

Apellis Pharmaceuticals (APLS) reported net product sales of approximately $138 million in the United States for the fourth quarter of 2023, up significantly year over year. The company generates product revenues from the sale of its two marketed drugs, Empaveli (pegcetacoplan) and Syfovre (pegcetacoplan injection). Its top line also comprises of licensing and other revenues.The 39% sequential increase in product revenues (from $99.2 million) was driven by strong Syfovre sales. Syfovre recorded sales of $11 ...

Apellis Pharmaceuticals, Inc. (APLS) shares ended the last trading session 14.7% higher at $68.35. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5% loss over the past four weeks.The sudden rise in the stock price can be attributed to the strong preliminary net product revenues reported in the United States for the fourth quarter and full year 2023. Apellis' marketed portfolio of drugs comprise Empaveli (pegcetaco ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants Cedric Francois - Co-Founder and CEO Tim Sullivan - CFO Adam Townsend - CCO Caroline Baumal - CMO Meredith Kaya - SVP, IR Conference Call Participants Jonathan Miller - Evercore Tazeen Ahmad - Bank of America Anupam Rama - JPMorgan Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Phil Nadeau - TD Cowen Derek Archila - Wells Fargo Eliana Merle - UBS Akash Tewari - Jeffer ...